Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Ultragenyx (NASDAQ: RARE) granted 18,180 restricted stock units (RSUs) to 12 newly hired non-executive officers under the Ultragenyx Employment Inducement Plan.

The awards were approved by the compensation committee, granted with a November 16, 2025 grant date and issued as an inducement under Nasdaq Listing Rule 5635(c)(4). The RSUs vest over four years with 25% vesting on each anniversary subject to continued employment.

NOVATO, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 18,180 restricted stock units of the company’s common stock to 12 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of November 16, 2025, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).

The restricted stock units vest over four years, with 25% of the underlying shares vesting on each anniversary of the grant date, subject to the employee being continuously employed by the company as of such vesting dates.

About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.

Contact Ultragenyx
Investors & Media
Joshua Higa
(415) 475-6370

FAQ

What did Ultragenyx (RARE) announce on November 21, 2025 about inducement grants?

Ultragenyx announced the grant of 18,180 RSUs to 12 newly hired non-executive officers as inducements under Nasdaq Rule 5635(c)(4).

How do the RSUs granted by Ultragenyx (RARE) vest and when is the grant date?

The RSUs vested over four years with 25% vesting on each anniversary; the grant date was November 16, 2025.

Which employees received the inducement RSUs from Ultragenyx (RARE)?

The awards were granted to 12 newly hired non-executive officers as part of their inducement to join the company.

Why did Ultragenyx (RARE) grant RSUs under Nasdaq Listing Rule 5635(c)(4)?

The company used the inducement plan to issue equity awards that are material to new employees entering employment in accordance with Nasdaq Rule 5635(c)(4).

Will the Ultragenyx (RARE) RSU grants immediately dilute existing shareholders?

The announcement states the grant size (18,180 RSUs) but does not quantify dilution or outstanding share count, so immediate dilution impact was not disclosed.